Earnings ·
BridgeBio Oncology reports $56.5M net loss for Q2, holds $344.1M in cash
BBOTBridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $56.5 million and spent $49.2 million on research and development, driven by increased clinical trial costs. General and administrative expenses rose to $11.0 million due to standalone operations following its de-SPAC transaction. As of June 30, the firm held $344.1 million in cash and marketable securities, providing a runway into 2028. Clinically, BBOT initiated dosing for BBO-11818 with cetuximab and presented preclinical data at AACR. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS-pathway malignancies.